公开(公告)号：EP1062199A1

公开(公告)日：2000-12-27

申请号：EP99907333.1

申请日：1999-03-11

申请人： NOVO NORDISK A/S ,  Ontogen Corporation

发明人： RICHTER, Lutz Stefan ,  ANDERSEN, Henrik, Sune ,  VAGNER, Josef ,  JEPPESEN, Claus, Bekker ,  MOLLER, Niels, Peter, Hundahl ,  BRANNER, Sven ,  SU, Jing ,  BAKIR, Farid ,  JUDGE, Luke, Milburn

IPC分类号： C07C235/84 ,  C07D213/55 ,  C07D239/28 ,  C07D241/24 ,  A61K31/17 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505

摘要： The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

公开(公告)号：EP1080068A1

公开(公告)日：2001-03-07

申请号：EP99907336.4

申请日：1999-03-12

申请人： Novo Nordisk A/S ,  Ontogen Corporation

发明人： RICHTER, Lutz Stefan ,  ANDERSEN, Henrik Sune ,  VAGNER, Josef ,  JEPPESEN, Claus, Becker ,  MOELLER, Niels P H ,  BRANNER, Sven ,  JEPPESEN, Lone ,  OLSEN, Ole Hvilsted ,  IVERSEN, Lars Fogh ,  HOLSWORTH, Daniel Dale ,  AXE, Frank Urban ,  GE, Yu ,  JONES, Todd, Kevin ,  RIPKA, William Charles ,  UYEDA, Roy Teruyuki ,  SU, Jing ,  BAKIR, Farid ,  JUDGE, Luke Milburn

IPC分类号： C07C235/84

CPC分类号： C07D213/79 ,  C07C233/56 ,  C07C237/22 ,  C07D207/34 ,  C07D209/08 ,  C07D209/14 ,  C07D213/80 ,  C07D231/40 ,  C07D239/42 ,  C07D239/557 ,  C07D241/26 ,  C07D261/08 ,  C07D271/07 ,  C07D271/10 ,  C07D271/113 ,  C07D333/38 ,  C07D333/66 ,  C07D333/68 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D495/04 ,  C07D495/10 ,  C07D495/14

摘要： The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPν, PTPδ, PTPσ, PTPz, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes.

公开(公告)号：EP1183229B1

公开(公告)日：2005-10-26

申请号：EP00926725.3

申请日：2000-05-16

申请人： NOVO NORDISK A/S ,  AGOURON PHARMACEUTICALS, INC.

发明人： LING, Anthony ,  PLEWE, Michael, Bruno ,  TRUESDALE, Larry, Kenneth ,  LAU, Jesper ,  MADSEN, Peter ,  SAMS, Christian ,  BEHRENS, Carsten ,  VAGNER, Josef ,  CHRISTENSEN, Inge, Thoger ,  LUNDT, Behrend, Frederik ,  SIDELMANN, Ulla, Grove ,  THOGERSEN, Henning ,  KODRA, János, Tibor

IPC分类号： C07C237/32 ,  C07C243/24 ,  C07C271/40 ,  C07C275/28 ,  C07D209/48 ,  C07D257/04 ,  C07D333/04 ,  A61K31/15 ,  A61K31/165 ,  A61K31/17 ,  A61K31/33 ,  A61P3/04 ,  A61P3/10

CPC分类号： C07D209/48 ,  C07B2200/07 ,  C07C237/36 ,  C07C237/42 ,  C07C243/38 ,  C07C271/56 ,  C07C271/58 ,  C07C275/24 ,  C07C275/26 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/36 ,  C07C275/38 ,  C07C275/42 ,  C07C275/60 ,  C07C275/62 ,  C07C311/47 ,  C07C317/22 ,  C07C317/32 ,  C07C317/42 ,  C07C323/21 ,  C07C323/44 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/42 ,  C07C2603/18 ,  C07C2603/68 ,  C07C2603/94 ,  C07D209/08 ,  C07D211/58 ,  C07D213/75 ,  C07D215/38 ,  C07D231/40 ,  C07D235/30 ,  C07D257/06 ,  C07D277/72 ,  C07D295/13 ,  C07D295/135 ,  C07D307/68 ,  C07D317/66 ,  C07D319/18 ,  C07D319/20 ,  C07D333/20 ,  C07D333/38 ,  C07D333/60 ,  C07D333/68 ,  C07D333/70 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

公开(公告)号：EP1183229A1

公开(公告)日：2002-03-06

申请号：EP00926725.3

申请日：2000-05-16

申请人： NOVO NORDISK A/S ,  AGOURON PHARMACEUTICALS, INC.

发明人： LING, Anthony ,  PLEWE, Michael, Bruno ,  TRUESDALE, Larry, Kenneth ,  LAU, Jesper ,  MADSEN, Peter ,  SAMS, Christian ,  BEHRENS, Carsten ,  VAGNER, Josef ,  CHRISTENSEN, Inge, Thoger ,  LUNDT, Behrend, Frederik ,  SIDELMANN, Ulla, Grove ,  THOGERSEN, Henning

IPC分类号： C07C237/32 ,  C07C243/24 ,  C07C271/40 ,  C07C275/28 ,  C07D209/48 ,  C07D257/04 ,  C07D333/04 ,  A61K31/15 ,  A61K31/165 ,  A61K31/17 ,  A61K31/33 ,  A61P3/04 ,  A61P3/10

CPC分类号： C07D209/48 ,  C07B2200/07 ,  C07C237/36 ,  C07C237/42 ,  C07C243/38 ,  C07C271/56 ,  C07C271/58 ,  C07C275/24 ,  C07C275/26 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/36 ,  C07C275/38 ,  C07C275/42 ,  C07C275/60 ,  C07C275/62 ,  C07C311/47 ,  C07C317/22 ,  C07C317/32 ,  C07C317/42 ,  C07C323/21 ,  C07C323/44 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/42 ,  C07C2603/18 ,  C07C2603/68 ,  C07C2603/94 ,  C07D209/08 ,  C07D211/58 ,  C07D213/75 ,  C07D215/38 ,  C07D231/40 ,  C07D235/30 ,  C07D257/06 ,  C07D277/72 ,  C07D295/13 ,  C07D295/135 ,  C07D307/68 ,  C07D317/66 ,  C07D319/18 ,  C07D319/20 ,  C07D333/20 ,  C07D333/38 ,  C07D333/60 ,  C07D333/68 ,  C07D333/70 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

摘要： A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

摘要翻译： 一类新颖的化合物，其作用是拮抗胰高血糖素激素对胰高血糖素受体的作用。 由于它们对胰高血糖素受体的拮抗作用，所述化合物可适用于治疗和/或预防任何胰高血糖素介导的病症和疾病如高血糖症，1型糖尿病，2型糖尿病和肥胖症。